Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children.

Transplantation proceedings - 1 Mar 2016

Alvarez-Elías A C, García-Roca P, Velásquez-Jones L, Valverde S, Varela-Fascinetto G, Medeiros M

Abstract excerpt

BACKGROUND: CYP3A5 gene polymorphism rs776746 has been associated with lower tacrolimus dose requirements and bioavailability in both adults and children. This variant causes a loss of CYP3A5 activity owing to a splice site variant leading to a truncated inactive enzyme. The aim of this study was to determine if the rs776746 gene polymorphism is related to the time to reach tacrolimus therapeutic levels in renal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biological Availability

Share to Cytochrome P-450 CYP3A

Share to Graft Rejection

Share to Graft Survival

Share to Immunosuppressive Agents

Share to Kidney Transplantation

Share to Tacrolimus

Share to Tissue Donors

Source

Identifiers

PMID: 27110018
DOI: 10.1016/j.transproceed.2016.02.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children.PMID 27110018Read ↗

A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation.Semantic proximity Read ↗

Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients.Semantic proximity Read ↗

Impact of CYP3A5 1* and 3* single nucleotide variants on tacrolimus pharmacokinetics and graft rejection risk in pediatric kidney transplant patientsSemantic proximity Read ↗

Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.Semantic proximity Read ↗

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatmentSemantic proximity Read ↗

CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing.Semantic proximity Read ↗

CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies.Semantic proximity Read ↗

Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes.Semantic proximity Read ↗

CYP3A5 Expressor Genotype of the Transplanted Kidney Increases the Risk of Preterm Graft Loss and Acute Rejection.Semantic proximity Read ↗

Genotype-guided tacrolimus dosing: The role of CYP3A5 polymorphisms in optimising kidney transplant immunosuppression in BhutanSemantic proximity Read ↗

Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.